All In Biotech

Drug Trial Radar · NCT04504812

A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain

Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,937 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,937

Actual

Start

Feb 1, 2021

Primary completion

Apr 8, 2025

Study completion Apr 8, 2025

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Pacira Pharmaceuticals, Inc
First posted
Aug 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There is an urgent public health need to reduce reliance on opioids for effective long-term pain management, particularly in knee osteoarthritis (KOA). This effectiveness trial will compare commonly recommended treatments to reduce pain and functional limitations in KOA.These results will lead to improved patient selection for treatment and inform evidence based guidelines by offering well-tested, effective, non-surgical alternatives.

Conditions

  • Knee Osteoarthritis

Interventions

  • DuloxetineDrug

    Duloxetine is a drug that is used to improve pain and function in people with knee osteoarthritis (KOA). Duloxetine is approved by the Food and Drug Administration (FDA) for the treatment of depression, anxiety disorder, fibromyalgia, and joint pain. It will be titrated up from 20 or 30mg according to a schedule provided by a study provider.

  • Intra-Articular InjectionCombination product

    Intra-Articular Injection is an injection of 3-6 milliliter (mL) hyaluronic acid (HA) mixed with 1 milliliter (mL) depo methylprednisolone (a steroid) and 2 mL 0.5% bupivacaine (an anesthetic) into the knee.

  • Nerve Procedure with long acting blocksProcedure

    People assigned to receive this will have 1 milliliter (mL) of a long-acting local anesthetic (a.k.a. liposomal bupivacaine or EXPAREL) and steroid injected into the knee.

  • Nerve Procedure with nerve ablationProcedure

    People assigned to receive this will have heat applied to destroy the nerve signaling pain in the knee. Steroid will be administered after the procedure to reduce the risk of neuritis.

  • Pain Coping Skills TrainingBehavioral

    Participants will be provided with a written manual that includes login information for the pain coping skills training website. The participants will be expected to log into the system weekly, work through the modules, and participate in skills practice.

  • Best PracticesOther

    Best Practices can include topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen; physical therapy that may include aquatherapy; integrative treatments such as acupuncture, yoga, or a structured exercise program; and other non-invasive treatments.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Pain Intensity as assessed by the Modified 4-item Brief Pain Inventory (BPI) Pain ScaleTime frame: Change from Baseline to 8 weeks post-randomization (mITT) and to 8 weeks post-treatment (per protocol) in Phase 1; Change from Baseline to 12 weeks post-randomization (mITT) and to 12 weeks post-treatment (per protocol) in Phase 2

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • University of California Davis

    Sacramento, California

  • University of California San Diego

    San Diego, California

  • VA Medical Center San Diego

    San Diego, California

  • University of Colorado

    Aurora, Colorado

  • University of Florida

    Gainesville, Florida

  • Emory University

    Atlanta, Georgia

  • Atlanta VA Medical Center

    Decatur, Georgia

  • Northwestern University

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • Johns Hopkins

    Baltimore, Maryland

  • Walter Reed Army Medical Center

    Bethesda, Maryland

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • University of Minnesota

    Minneapolis, Minnesota

  • Weill Cornell University

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Wake Forest University

    Winston-Salem, North Carolina

  • Cleveland VA Medical Center

    Cleveland, Ohio

  • University Hospitals

    Cleveland, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Vanderbilt University

    Nashville, Tennessee

  • University of Utah

    Salt Lake City, Utah

  • University of Virginia

    Charlottesville, Virginia

  • University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.